36132-96-4Relevant articles and documents
Synthesis and isolation of some benzo[c]tellurophenes
Huang, Zhizhen,Lakshmikantham,Lyon, Michael,Cava, Michael P.
, p. 5413 - 5415 (2000)
-
Syntheses of new hydroxy-[3.3]orthocyclophanes as models for the galactose oxidase Tyr-Cys cofactor
Liu, Xiaoming,Barrett, Simon A,Kilner, Colin A,Thornton-Pett, Mark,Halcrow, Malcolm A
, p. 603 - 611 (2002)
The syntheses of 3,4-benzo-8,9-(3′-hydroxybenzo)bicyclo[4,4,1]undeca-3,8-dien-11-one, 3,4-benzo-8,9-(3′-hydroxy-4′-methylsulfanylbenzo)bicyclo[4,4,1] undeca-3,8-dien-11-one and their ethylene acetals have been achieved. Crystallographic, UV/Vis and NMR data show that the two ketones adopt boat/chair conformations that are fluxional in solution, while the acetals exhibit chair/chair conformations with layered benzo rings. Comparison of the oxidation potentials of the four compounds suggests that an ortho-methylsulfanyl substituent and a π-π interaction both thermodynamically stabilise the phenoxonium radical species derived from these compounds, by approximately equal amounts.
A Spiroalkylation Method for the Stereoselective Construction of α-Quaternary Carbons and Its Application to the Total Synthesis of (R)-Puraquinonic Acid
Elmehriki, Adam A. H.,Gleason, James L.
supporting information, p. 9729 - 9733 (2019/12/02)
Cyclic α-quaternary carbon stereocenters were prepared from biselectrophillic substrates and an easily prepared chiral bicyclic sulfonyl lactam. This was achieved in two steps by spiroalkylation, employing biphasic reaction conditions with a phase-transfer catalyst, followed by reduction and alkylation with a series of alkyl halide electrophiles. The products of this method were isolated in good yields with with high levels of diastereoselectivity. This methodology was employed in the enantioselective total synthesis of (R)-puraquinonic acid (1) for a late-stage installation of the α-quaternary carbon stereocenter. This enabled the shortest synthesis of 1 to date, an eight-pot sequence providing an overall yield of 14%.
Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase
Gingrich, Diane E.,Lisko, Joseph G.,Curry, Matthew A.,Cheng, Mangeng,Quail, Matthew,Lu, Lihui,Wan, Weihua,Albom, Mark S.,Angeles, Thelma S.,Aimone, Lisa D.,Haltiwanger, R. Curtis,Wells-Knecht, Kevin,Ott, Gregory R.,Ghose, Arup K.,Ator, Mark A.,Ruggeri, Bruce,Dorsey, Bruce D.
experimental part, p. 4580 - 4593 (2012/07/28)
Anaplastic lymphoma kinase (ALK) is a promising therapeutic target for the treatment of cancer, supported by considerable favorable preclinical and clinical activities over the past several years and culminating in the recent FDA approval of the ALK inhib
